dc.contributor.author |
KHALID KHAN, MUHAMMAD |
|
dc.contributor.author |
FARID KHAN, MUHAMMAD |
|
dc.date.accessioned |
2022-11-29T05:19:21Z |
|
dc.date.available |
2022-11-29T05:19:21Z |
|
dc.date.issued |
2008-07-17 |
|
dc.identifier.citation |
Khan, M. K., & Khan, M. F. (2008). Assessment of bioequivalence of ciprofloxacin in healthy male subjects using HPLC. Pakistan Journal of Pharmaceutical Sciences, 21(3). |
en_US |
dc.identifier.issn |
1011-601X |
|
dc.identifier.uri |
http://142.54.178.187:9060/xmlui/handle/123456789/14189 |
|
dc.description.abstract |
Pharmacokinetics and bioequivalence studies of two brands of ciprofloxacin 500mg (Ciprofloxacin & Ciproxin)
were evaluated in 14 healthy male volunteers after oral administration. The drug was analyzed in plasma
samples by using HPLC. The peak plasma concentrations of (2.28±0.04 mg/L) and (1.9±0.02 mg/L) was
attained in about 1.71 hours and 2.00 hours for both Test and Reference ciprofloxacin, respectively. The mean ± SE values for total area under the curve (AUC) were 11.91±0.26 and 13.11±0.27 h.mg/L for both test and
reference tablets respectively. This study indicated that all the differences in bioequivalence parameters for both ciprofloxacin formulations are statistically non-significant, hence both formulations are bioequivalent. |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
Karachi: Faculty of Pharmacy & Pharmaceutical Sciences, Karachi |
en_US |
dc.subject |
Ciprofloxacin two different formulations |
en_US |
dc.subject |
area under the curve |
en_US |
dc.subject |
peak plasma level |
en_US |
dc.subject |
time at which maximum concentration of drug |
en_US |
dc.title |
ASSESSMENT OF BIOEQUIVALENCE OF CIPROFLOXACIN IN HEALTHY MALE SUBJECTS USING HPLC |
en_US |
dc.type |
Article |
en_US |